Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Liver-directed therapies

20 evidence topics · 14 sources

Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants

“The multicenter, open-label, phase 3 FOCUS study was designed to evaluate the efficacy and safety of melphalan/HDS in patients with unresectable mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to slow enrollment, with patient reluctance to receive BAC treatment, the study design was amended to a single-arm study, after which all eligible patients received treatment with melphalan/HDS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study enrolled 102 patients with mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the treated population ( n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44–47.01), including 7.7 % of patients with a complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 9 months, with a PFS of 65 % at 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Melphalan percutaneous hepatic perfusion versus best alternative care: randomized portion of FOCUS, 85 participants

“The multicenter, open-label, Phase 3 FOCUS study was designed to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable mUM in comparison to best alternative care (BAC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study enrolled 85 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Eligible patients were randomized to receive Melphalan/HDS ( n = 43) or BAC ( n = 42), and 72 patients received study treatment (Melphalan/HDS [ n = 40]; BAC [ n = 32]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Isolated hepatic perfusion versus best alternative care: randomized phase 3 trial, response and progression-free survival

“In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There was one treatment-related death in the IHP group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Percutaneous hepatic perfusion with or without ipilimumab plus nivolumab: single-centre randomized phase 2 trial

“In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“One treatment-related death (due to triple M syndrome) occurred in the combination group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Hepatic arterial infusion, transarterial chemoembolization, and radioembolization: guideline summary